2 active not recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
Follow Standard Adjuvant Endocrine Therapy: new trials by email Literature Review of Standard Adjuvant Endocrine Therapy trials Research Report on Standard Adjuvant Endocrine Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer Abemaciclib, Standard Adjuvant Endocrine Therapy - Breast Cancer | Phase 3 | Active not recruiting | Eli Lilly and Company | 5637 | 2017-07-12 | 2026-04-24 |
| PALbociclib CoLlaborative Adjuvant Study Palbociclib, Standard Adjuvant Endocrine Therapy - Breast Cancer | Phase 3 | Active not recruiting | Alliance Foundation Trials, LLC. | 5796 | 2015-08-01 | 2026-06-15 |
Breast Neoplasms (2)
Alliance Foundation Trials, LLC. (1) · Eli Lilly and Company (1)
Australia (2) · Austria (2) · Belgium (2) · Canada (2) · Germany (2) · Hungary (2) · Israel (2) · Italy (2) · Japan (2) · Mexico (2) · Netherlands (2) · Poland (2) · Portugal (2) · South Korea (2) · Spain (2)
Angela DeMichele, MD (1) · Erica Mayer, MD (1) · Evanthia Galanis, MD (1) · Michael Gnant, MD (1)
PMID 30032196, PMID 32954927, PMID 33460574, PMID 34874182, PMID 34995105, PMID 35084948, PMID 35337972, PMID 35384873, PMID 35594464, PMID 35653145, PMID 36342342, PMID 36493792, PMID 37556775, PMID 37735004, PMID 38194616, PMID 39023253, PMID 39463748, PMID 39849600, PMID 40140172, PMID 41110697
2014 (1), 2016 (1)